This edition presents key opinion leader (KOL) views on recent developments in the Non-Hodgkin Lymphoma (NHL) market. Topics covered include: Roche announcing that the US FDA had granted priority review for polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab; Roche)(BR) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL); ADC Therapeutics announcing that the first patient had been dosed in a Phase I trial assessing ADCT-402 (loncastuximab tesirine) in combination with Imfinzi (durvalumab; AstraZeneca) in advanced DLBCL, mantle cell lymphoma and follicular lymphoma (FL); Celgene announcing that the US FDA had accepted a supplemental New Drug Application and granted priority review for Revlimid (lenlidomide) in combination with rituximab (R2) for the treatment of patients with previously treated FL and marginal zone lymphoma.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved